How Retatrutide Improves Blood Sugar Control in Type 2 Diabetes

Introduction

Type 2 diabetes affects more than 500 million people worldwide, and that number keeps rising. For most patients, controlling blood sugar means a lifelong balance of medication, diet, and discipline. Yet even with the best treatments available, many still struggle to keep glucose in check without side effects or weight gain.

That's why researchers are excited about Retatrutide (LY3437943), a new investigational drug from Eli Lilly that acts on three hormones at once: GLP-1, GIP, and glucagon. This so-called "triple agonist" doesn't just lower blood sugar—it aims to reset how the body manages energy, appetite, and metabolism.

Early trial results show Retatrutide produces dramatic improvements in blood sugar control while simultaneously delivering substantial weight loss. With TRIUMPH and TRANSCEND Phase 3 trials ongoing, Retatrutide could become the most powerful dual-purpose treatment yet for people living with type 2 diabetes.

Diabetes and the Hormones Behind It

Blood sugar regulation is like a constant conversation between several hormones.

• Insulin helps cells absorb glucose after a meal.
• Glucagon tells the liver to release glucose when you haven't eaten.
• Incretins like GLP-1 and GIP fine-tune both sides of that exchange.

In type 2 diabetes, this dialogue breaks down. The body stops responding properly to insulin, the pancreas gets overworked, and glucagon levels remain too high—so glucose keeps flooding the bloodstream.

Retatrutide steps in by mimicking all three key hormones in a carefully balanced way, restoring communication between them and allowing the body to use energy the way it was designed to.

How GLP-1, GIP, and Glucagon Work Together

GLP-1: The Satiety and Insulin Helper

GLP-1 tells your pancreas to release insulin when glucose is high, slows digestion, and helps you feel full faster. That's why drugs like Ozempic or Wegovy (both GLP-1 agonists) help with both blood sugar and weight.

In diabetes, GLP-1's insulin-stimulating effect is glucose-dependent, meaning it only works when blood sugar is elevated. This reduces the risk of dangerous hypoglycemia (low blood sugar) compared to older diabetes medications.

GIP: The Forgotten Hormone That Boosts Sensitivity

GIP was once thought to be "broken" in people with diabetes. New science shows it can actually enhance insulin sensitivity and reduce inflammation, especially when paired with GLP-1.

Tirzepatide (Mounjaro), a dual GLP-1/GIP agonist, demonstrated this potential by achieving superior glycemic control compared to semaglutide. Retatrutide takes this one step further by adding glucagon receptor activation.

Glucagon: The Fat-Burning Engine

Although glucagon raises blood sugar on its own, in small, controlled amounts it increases energy expenditure and fat burning. When balanced with GLP-1 and GIP, it helps the body burn stored fat instead of storing more.

This is particularly important for people with type 2 diabetes, where excess weight is both a cause and consequence of insulin resistance. By promoting fat loss, glucagon activation helps break this cycle.

The genius of Retatrutide lies in combining all three, leading to smoother glucose control, better insulin function, and faster metabolic improvements.

Clinical Data: Lower HbA1c, Better Fasting Glucose

Phase 2 Trial Results

In Eli Lilly's Phase 2 clinical trial, patients with type 2 diabetes who took Retatrutide saw HbA1c reductions of up to 2.02 percentage points after 24 weeks at the highest dose (12mg). For context:

• A 1% drop in HbA1c reduces the risk of diabetes complications by roughly 20%.
• A 2% drop is considered transformative and rare with medication alone.

Fasting glucose also improved significantly, dropping by an average of 50-60 mg/dL in those receiving higher doses. These improvements happened alongside dramatic weight loss—patients lost an average of 15-24% of body weight depending on the dose.

TRIUMPH-5: Phase 3 Diabetes Trial

TRIUMPH-5 is Eli Lilly's dedicated Phase 3 trial testing retatrutide specifically in patients with obesity and type 2 diabetes. While full results haven't been published yet (expected 2026), the trial is designed to confirm:

• HbA1c reduction comparable to or exceeding Phase 2 results
• Weight loss efficacy in diabetic populations
• Safety profile in patients on concurrent diabetes medications
• Potential for diabetes remission in some participants

Early indicators suggest retatrutide will maintain or exceed Phase 2 efficacy, potentially achieving:

• HbA1c reduction: 1.5-2.0 percentage points
• Weight loss: 20-28% body weight
• Diabetes remission rates: 30-50% (based on glycemic targets)

TRANSCEND Program: Diabetes-Focused Trials

Beyond TRIUMPH-5, Eli Lilly is conducting the TRANSCEND program—a series of Phase 3 trials specifically focused on diabetes outcomes:

TRANSCEND-1: Retatrutide vs placebo in type 2 diabetes patients
TRANSCEND-2: Retatrutide vs semaglutide head-to-head comparison
TRANSCEND-3: Retatrutide in patients with diabetic kidney disease

Results expected: 2026-2027

These trials will determine whether retatrutide becomes a first-line diabetes treatment, not just an obesity drug that also helps diabetes.

Weight Loss and Blood Sugar: Why They're Connected

One of the most powerful aspects of Retatrutide is that weight loss directly improves diabetes.

Here's why:

Fat Loss = Better Insulin Sensitivity

Excess fat, especially visceral fat around organs, releases inflammatory molecules that interfere with insulin signaling. Losing even 10% of body weight can dramatically improve insulin sensitivity.

With retatrutide achieving 28.7% weight loss in TRIUMPH-4 (and similar results expected in TRIUMPH-5), patients experience:

• Reduced pancreatic stress
• Lower insulin requirements
• Better glucose disposal
• Decreased need for additional diabetes medications

Dual Benefits in One Injection

Traditional diabetes medications often cause weight gain (insulin, sulfonylureas) or are weight-neutral (metformin). Retatrutide flips this paradigm:

‍

This dual benefit means patients not only achieve better blood sugar control but also address the root metabolic dysfunction driving their diabetes.

Who Could Benefit Most from Retatrutide?

Based on clinical trial evidence, retatrutide appears particularly promising for:

Type 2 Diabetes Patients with Obesity

• BMI ≥30 or ≥27 with complications
• HbA1c >7.5% despite current medication
• Struggling with weight on insulin or sulfonylureas
• Want to reduce or eliminate injectable insulin

Patients Plateauing on GLP-1 Drugs

• Already on semaglutide or tirzepatide
• Achieved initial benefits but hit a plateau
• Need additional HbA1c reduction
• Want greater weight loss

Those Seeking Diabetes Remission

• Recently diagnosed (within 5 years)
• Significant obesity (BMI >35)
• Still producing some insulin (C-peptide positive)
• Motivated for intensive therapy

Potential Diabetes Remission

One of the most exciting prospects is diabetes remission—defined as achieving normal blood sugar (HbA1c <6.5%) without diabetes medication for at least 3 months.

Can Retatrutide Cause Remission?

Early data suggests yes, for some patients:

Phase 2 substudy: Approximately 30-40% of participants achieved HbA1c <5.7% (prediabetic range) while on treatment.

Projected TRIUMPH-5 results: With 20-28% weight loss, an estimated 35-50% of patients may achieve remission criteria.

Key factors for remission:

• Shorter diabetes duration (<5 years)
• Higher baseline BMI (more weight to lose)
• Residual pancreatic function
• Commitment to lifestyle changes

However, remission typically requires continued treatment. Stopping retatrutide would likely lead to weight regain and diabetes recurrence—similar to what happens after bariatric surgery without long-term lifestyle adherence.

Side Effects and Safety in Diabetic Patients

Common Side Effects

Similar to other GLP-1 drugs:

• Nausea: 40-50% (usually mild, improves after dose titration)
• Diarrhea: 30-35%
• Vomiting: 15-20%
• Constipation: 10-15%

Dysesthesia (New Finding)

TRIUMPH-4 identified dysesthesia (abnormal touch sensations) in 20.9% of patients at 12mg dose. While generally mild, this warrants monitoring in diabetic patients who may already have peripheral neuropathy.

Hypoglycemia Risk

Low risk when used alone or with metformin.

Moderate risk when combined with:

• Insulin (dose reduction likely needed)
• Sulfonylureas (may need to discontinue)

Patients on these medications require close monitoring and proactive dose adjustments.

Diabetic Retinopathy

Like other rapid-glucose-lowering agents, retatrutide may temporarily worsen diabetic retinopathy in patients with existing eye disease. Gradual dose escalation and ophthalmology monitoring are recommended.

Comparison to Other Diabetes Medications

Retatrutide vs Tirzepatide (Mounjaro)

‍

Bottom line: Tirzepatide is excellent and available now. Retatrutide may offer incrementally better weight loss with similar glycemic control.

Retatrutide vs Semaglutide (Ozempic)

‍

Bottom line: Semaglutide has proven cardiovascular benefits. Retatrutide offers far superior weight loss but needs long-term CV data.

The Path Forward: TRIUMPH and TRANSCEND Trials

Timeline

2026:

• TRIUMPH-5 results (obesity + diabetes)
• TRANSCEND-1, 2, 3 results (diabetes-focused)
• Additional Phase 3 data

Late 2026/Early 2027:

• FDA submission for obesity and diabetes indications

2027-2028:

• FDA review and approval decision
• TRIUMPH Cardiovascular Outcomes Trial results

2028:

• Commercial launch (if approved)
• Potential dual indication: obesity + type 2 diabetes

What Approval Could Look Like

Likely FDA Indications:

1. Chronic weight management (BMI ≥30 or ≥27 with comorbidity)
2. Type 2 diabetes (as adjunct to diet and exercise)

Potential Additional Indications (if trials support):

• Diabetic kidney disease (TRANSCEND-3 data)
• Cardiovascular risk reduction (if CVOT positive)
• MASLD/NASH (liver disease, Phase 2a data)

What This Means for Diabetes Treatment

Retatrutide represents a paradigm shift in diabetes care:

From Management to Reversal

Current treatments manage diabetes. Retatrutide may help reverse the metabolic dysfunction:

• Dramatic weight loss addresses root cause (obesity)
• Improved insulin sensitivity reduces medication burden
• Potential remission in some patients
• Comprehensive metabolic reset

One Drug, Multiple Benefits

Instead of:

• Metformin for blood sugar
• Statins for cholesterol
• Blood pressure medications
• Separate weight loss drugs

Retatrutide may address:

• Glycemic control ✓
• Weight loss ✓
• Lipid improvements ✓
• Blood pressure reduction ✓
• Liver fat reduction ✓

The Future of Precision Medicine

TRANSCEND trials may reveal which diabetic patients benefit most:

• Duration of diabetes
• Degree of insulin resistance
• Pancreatic reserve (C-peptide levels)
• Genetic markers

This could enable personalized treatment selection rather than one-size-fits-all approaches.

Conclusion

Retatrutide's triple-hormone mechanism offers a fundamentally different approach to type 2 diabetes treatment. By simultaneously targeting appetite, insulin sensitivity, and energy expenditure, it addresses multiple pathways in metabolic disease.

Phase 2 data showing 2% HbA1c reduction alongside 20-24% weight loss represents a major advancement. If TRIUMPH-5 and TRANSCEND trials confirm these results in larger diabetic populations, retatrutide could become:

• The most effective weight-loss medication for diabetic patients
• A potential path to diabetes remission for some
• A comprehensive metabolic therapy addressing root causes

Challenges remain: long-term safety data, cardiovascular outcomes, cost, and accessibility. But for the millions living with type 2 diabetes and obesity, retatrutide offers hope for a treatment that doesn't just manage symptoms but helps restore metabolic health.

Expected approval and launch in 2028 means patients and clinicians have time to monitor ongoing trials and prepare for what could be the most significant diabetes treatment advancement in years.

Sources:

• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023
• Eli Lilly Phase 2 diabetes substudy data
• ClinicalTrials.gov TRIUMPH-5 and TRANSCEND trial registrations